These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11005934)

  • 21. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
    Lordkipanidzé M; Pharand C; Palisaitis DA; Schampaert E; Diodati JG
    Thromb Res; 2009 Nov; 124(5):546-53. PubMed ID: 19419755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.
    Plicner D; Mazur P; Hymczak H; Stoliński J; Litwinowicz R; Drwiła R; Undas A
    Thromb Res; 2015 Sep; 136(3):519-25. PubMed ID: 26003782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
    Kaufman JS; O'Connor TZ; Zhang JH; Cronin RE; Fiore LD; Ganz MB; Goldfarb DS; Peduzzi PN;
    J Am Soc Nephrol; 2003 Sep; 14(9):2313-21. PubMed ID: 12937308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
    Fukushima K; Kobayashi Y; Kitahara H; Iwata Y; Kuroda N; Ooyama M; Kuwabara Y; Nomura F; Komuro I
    Heart Vessels; 2010 Jan; 25(1):41-4. PubMed ID: 20091397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
    Kim JS; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W; Jeong KH
    Int J Cardiol; 2017 Jul; 238():110-116. PubMed ID: 28342632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.
    Jain N; Li X; Adams-Huet B; Sarode R; Toto RD; Banerjee S; Hedayati SS
    Am J Cardiol; 2016 Feb; 117(4):656-663. PubMed ID: 26725101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100.
    Madsen EH; Schmidt EB; Maurer-Spurej E; Kristensen SR
    Platelets; 2008 Aug; 19(5):335-41. PubMed ID: 18791939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.
    Lecka J; Rana MS; Sévigny J
    Br J Pharmacol; 2010 Nov; 161(5):1150-60. PubMed ID: 20977463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to aspirin and clopidogrel monitored with different platelet function methods.
    Mani H; Linnemann B; Luxembourg B; Kirchmayr K; Lindhoff-Last E
    Platelets; 2006 Aug; 17(5):303-10. PubMed ID: 16928602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
    Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C
    Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.
    Schumacher WA; Bostwick JS; Ogletree ML; Stewart AB; Steinbacher TE; Hua J; Price LA; Wong PC; Rehfuss RP
    J Pharmacol Exp Ther; 2007 Jul; 322(1):369-77. PubMed ID: 17420297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks® assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study.
    den Toom ML; van Leeuwen MW; Szatmári V; Teske E
    Vet Q; 2017 Dec; 37(1):8-15. PubMed ID: 27786603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
    Mazur P; Frołow M; Niżankowski R; Sadowski J; Undas A
    Platelets; 2013; 24(2):151-5. PubMed ID: 22497730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition.
    Hobson AR; Qureshi Z; Banks P; Curzen NP
    Platelets; 2009 Sep; 20(6):386-90. PubMed ID: 19811222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.